Gill, Sharlene <br/><br/>
End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival?  [electronic resource] 

 -  The oncologist  Jun 2006 
 - 624-9 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1083-7159 
<br/><br/><label>Standard No.: </label>10.1634/theoncologist.11-6-624  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Breast Neoplasms--drug therapy<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Chemotherapy, Adjuvant<br/>Colonic Neoplasms--drug therapy<br/>Disease-Free Survival<br/>Endpoint Determination<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Neoplasms--drug therapy<br/>Survival Rate